Related Experiment Videos
Practical issues in the development of argatroban: a perspective
Jawed Fareed1, Debra Hoppensteadt, Omer Iqbal
1Departments of Pathology and Pharmacology, Loyola University Medical Center, Maywood, IL 60153, USA. jfareed@lumc.edu
Pathophysiology of Haemostasis and Thrombosis
|June 18, 2003
Summary
Argatroban, a synthetic antithrombin, offers potent anticoagulation and unique cellular modulation. It provides stronger inhibition of thrombin generation than heparins or hirudins without antibody formation.
Area of Science:
- Pharmacology
- Biochemistry
- Cell Biology
Background:
- Argatroban is the first approved synthetic antithrombin agent.
- It exhibits unique pharmacological properties, including reversible antithrombin activity.
- It modulates endothelial cell function and reduces inflammatory/thrombotic cytokines.
Purpose of the Study:
- To evaluate the pharmacological profile of argatroban.
- To compare its anticoagulant efficacy and mechanism with other antithrombin agents.
- To explore its potential for expanded clinical indications.
Main Methods:
- Comparative analysis of anticoagulant effects at equivalent activated clotting time (ACT) levels.
- Assessment of thrombin generation inhibition using markers like F(1.2) and thrombin-antithrombin complex.
- Evaluation of antibody generation and need for dosage adjustments.
Main Results:
- Argatroban demonstrates a stronger anticoagulant effect than heparins and hirudins at comparable ACT.
- It significantly inhibits thrombin generation more effectively than other agents.
- Argatroban does not induce antibody formation, eliminating the need for dosage adjustments.
Conclusions:
- Argatroban possesses a unique pharmacological profile, combining potent anticoagulation with cellular function modulation.
- Its efficacy in inhibiting thrombogenesis and lack of antibody generation support its clinical utility.
- The broad actions of argatroban suggest potential for wider therapeutic applications.